142 related articles for article (PubMed ID: 9921985)
1. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.
Borsellino N; Bonavida B; Ciliberto G; Toniatti C; Travali S; D'Alessandro N
Cancer; 1999 Jan; 85(1):134-44. PubMed ID: 9921985
[TBL] [Abstract][Full Text] [Related]
2. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Borsellino N; Belldegrun A; Bonavida B
Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor.
Mori S; Murakami-Mori K; Bonavida B
Anticancer Res; 1999; 19(2A):1011-5. PubMed ID: 10368647
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
6. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
7. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
9. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
Liautard J; Sun RX; Cotte N; Gaillard JP; Mani JC; Klein B; Brochier J
Cytokine; 1997 Apr; 9(4):233-41. PubMed ID: 9112331
[TBL] [Abstract][Full Text] [Related]
11. IL-6 signal transduction and its physiological roles: the signal orchestration model.
Kamimura D; Ishihara K; Hirano T
Rev Physiol Biochem Pharmacol; 2003; 149():1-38. PubMed ID: 12687404
[TBL] [Abstract][Full Text] [Related]
12. Cytokines involving gp130 in signal transduction suppressed growth of a mouse hybridoma cell line and enhanced its antibody production.
Terada S; Suzuki E; Ueda H; Makishima F
Cytokine; 1996 Dec; 8(12):889-94. PubMed ID: 9050746
[TBL] [Abstract][Full Text] [Related]
13. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms mediating the inhibitory effect of all-trans retinoic acid on primitive hematopoietic stem cells in human long-term bone marrow culture.
Sammons J; Ahmed N; Khokher MA; Hassan HT
Stem Cells; 2000; 18(3):214-9. PubMed ID: 10840075
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130.
Howlett M; Judd LM; Jenkins B; La Gruta NL; Grail D; Ernst M; Giraud AS
Gastroenterology; 2005 Sep; 129(3):1005-18. PubMed ID: 16143138
[TBL] [Abstract][Full Text] [Related]
17. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
18. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
19. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130).
Geisterfer M; Richards CD; Gauldie J
Cytokine; 1995 Aug; 7(6):503-9. PubMed ID: 8580365
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity.
Sun RX; Gennaro C; Rocco S; Gu ZJ; Klein B
Eur Cytokine Netw; 1997 Mar; 8(1):51-6. PubMed ID: 9110148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]